Titan Pharmaceuticals (TTNP) Quick Liquidity Indicator

titanpharm.com (TTNP) - corporate logo

This daily price chart for Titan Pharmaceuticals (TTNP) on GURU.Markets at 12.04 highlights financial pressure stemming from liquidity shortages and past crises. Titan Pharmaceuticals (TTNP) relies on its innovative ProNeura system to create implants for prolonged drug delivery. The company generates revenue from the sale of treatments combating opioid cravings while exploring the platform's potential for treating chronic pathologies.

titanpharm.com (TTNP) - Critical Liquidity Ratio from 07/04/2022 to 10/18/2025

Titan Pharmaceuticals (TTNP) - metric breakdowns and financial figures

- market value and analyst target forecast:
Price Chart titanpharm.com|TTNP - Average Forecast Price
- market capitalization details:
Market Valuation Titan Pharma|TTNP - Value Adjusted for Debt and Cash
- book capitalization indicators:
Book Value per Share Titan Pharmaceuticals|TTNP - Net Asset Value|Market Capitalization to Book Value Ratio titanpharm.com|TTNP - Company Total Assets
- business debt structure and liquidity details:
Debt to Equity Titan Pharmaceuticals|TTNP - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity titanpharm.com|TTNP - Company Total Debt|Debt to Book Value Titan Pharma|TTNP - Amount of Long-Term Liabilities|Company Short-Term Debts Titan Pharmaceuticals|Quick Liquidity Indicator titanpharm.com
- earnings and valuation multiples indicators:
TTNP - Profit After Payment of Taxes
Basic company analysis:Titan Pharmaceuticals Inc., TTNP
Manufactured product of titanpharm.com

Titan Pharmaceuticals is striving to optimize operational processes within the biopharmaceutical segment. The quick liquidity trajectory reflects the company's ability to cover short-term liabilities solely through cash and accounts receivable, ignoring low-liquidity inventories. For an issuer with a high dependency on a single implant platform, this margin of safety is critically important when seeking new strategies. A high ratio minimizes default risk, thereby stabilizing quotes.

Competitor analysis for Titan Pharmaceuticals

Indivior Group (INDV) - Quick Liquidity|Immediate Liquidity Collegium Corp (COLL)|Quick Liquidity Indicator CRON|CGC: Intermediate Coverage Ratio|Quick Ratio HITI|ACB: Critical Liquidity Ratio|Quick Ratio ACHV (Achieve Life Sciences, Inc)|Quick Ratio Skye Bioscience Inc. SKYE|ANEB - Quick Liquidity|Intermediate Coverage Ratio INCR (InterCure Ltd.)|nutriband.com (NTRB) - Quick Liquidity|Quick Liquidity Indicator Nasus Pharma|Quick Liquidity Indicator IGC|MIRA (MIRA Pharma) - Intermediate Liquidity Ratio|Quick Ratio FLGC|Interim Coverage Ratio imcannabis.com|Adial Pharmaceuticals, Inc. - Quick Liquidity Indicator|Intermediate Liquidity Ratio ARTL (Artelo Biosciences Inc.)|Ensysce - Quick Ratio|GNLN - Quick Ratio|InMed Pharmaceuticals (INM) - Quick Liquidity|Immediate Liquidity Ratio AKAN|Quick Liquidity Indicator ENVB|BGXX: Intermediate Coverage Ratio|Quick Liquidity Hempacco Co., Inc. (HPCO)